I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for past performance.

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening with the Cologuard ® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoring ABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain.

Axxcess Wealth Management LLC lessened its stake in Abbott Laboratories (NYSE: ABT) by 67.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,628 shares of the healthcare product maker's stock after selling 64,579 shares during the period. Axxcess Wealth Management LLC's

Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.

Abbott Laboratories NYSE: ABT delivered its third-quarter earnings report on Oct. 21. The stock dropped about 4% in early trading, as the results were merely solid, at a time when investors wanted something spectacular.

Abbott announced a tax-free spin-off of its nutrition business. Third-quarter comparable sales grew 7% year over year.

Abbott Laboratories will spin off its Nutrition division, aiming to sharpen focus on higher-growth diagnostics, medical devices, and established pharmaceuticals. ABT's Q3 revenues rose 14.5% year-on-year to $13.01bn, with Diagnostics (boosted by the Exact Sciences acquisition) and Medical Devices as key growth drivers. 2026 adjusted EPS guidance narrowed to $5.50–$5.55; management expects the spin-off to enable higher growth and improved profitability for ABT.

/PRNewswire/ -- Stock Preachers News Commentary - Three sessions into the week, growth and small caps are setting the pace. The Nasdaq Composite jumped 1.04%